EVs carrying NKG2D ligands (MIC-A/B and ULBPs) decrease the NKG2D expressions on NK cells and impair NKG2D-mediated NK cell cytotoxicity in acute myeloid leukemia, mesothelioma, prostate, and breast cancer cells [34,35,36]. The gene discussed is KLRK1; the disease is breast carcinoma.